Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $182,953 | $17,447 | $25,816 | $57,027 |
| % Growth | 948.6% | -32.4% | -54.7% | – |
| Cost of Goods Sold | $12,826 | $1,593 | $955 | $2,075 |
| Gross Profit | $170,127 | $15,854 | $24,861 | $54,952 |
| % Margin | 93% | 90.9% | 96.3% | 96.4% |
| R&D Expenses | $53,386 | $50,312 | $42,624 | $41,712 |
| G&A Expenses | $0 | $0 | $44,949 | $25,397 |
| SG&A Expenses | $237,310 | $108,700 | $44,949 | $25,397 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $290,696 | $159,012 | $87,573 | $67,109 |
| Operating Income | -$120,569 | -$143,158 | -$62,712 | -$12,157 |
| % Margin | -65.9% | -820.5% | -242.9% | -21.3% |
| Other Income/Exp. Net | $5,015 | $7,265 | $617 | -$1,615 |
| Pre-Tax Income | -$115,554 | -$135,893 | -$62,095 | -$13,772 |
| Tax Expense | $0 | $0 | -$4 | $55 |
| Net Income | -$115,554 | -$135,893 | -$62,091 | -$13,827 |
| % Margin | -63.2% | -778.9% | -240.5% | -24.2% |
| EPS | -3.07 | -4.62 | -2.52 | -0.67 |
| % Growth | 33.5% | -83.3% | -276.1% | – |
| EPS Diluted | -3.07 | -4.62 | -2.52 | -0.67 |
| Weighted Avg Shares Out | 37,605 | 29,383 | 24,620 | 20,554 |
| Weighted Avg Shares Out Dil | 37,605 | 29,383 | 24,620 | 20,554 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15,014 | $10,337 | $3,499 | $36 |
| Interest Expense | $7,447 | $3,225 | $2,064 | $0 |
| Depreciation & Amortization | $1,225 | $877 | $326 | $312 |
| EBITDA | -$106,480 | -$131,670 | -$59,705 | -$13,460 |
| % Margin | -58.2% | -754.7% | -231.3% | -23.6% |